Literature DB >> 18499881

Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold.

Amber Cronk1, Tammy L Humphries, Thomas Delate, Denese Clark, Barbara Morris.   

Abstract

PURPOSE: The mechanisms used by Medicare beneficiaries who reached their Part D drug-benefit threshold to cope with the costs of prescription drugs were evaluated.
METHODS: A retrospective review of integrated medical and pharmacy electronic records and a mail survey were utilized. Members of a Medicare Advantage plan continuously enrolled in 2006 in either a standard drug-benefit plan who reached their threshold by October 1, 2006 (study group) or a retiree drug subsidy plan without a threshold but by October 1, 2006, had reached the threshold in total drug spend (control group) were included. Data on members' cost-lowering medication strategies, demographics, and socioeconomic status were analyzed.
RESULTS: Of the 1,472 questionnaires mailed, 622 (42%) were completed. Respondents in the study group were more likely than control respondents to be male, be married, own a home, report lower health status, and have a household income of <$30,000 (p < 0.05). There were no significant differences in age, race or ethnicity, and diagnoses between groups. Study group respondents were three times more likely than control group respondents to use a cost-lowering strategy (p < 0.001). Predictors of increased risk of using a medication cost-lowering strategy included study group assignment, age, health status, education, income, and purchase of a second-generation antipsychotic (p < 0.05).
CONCLUSION: Respondents in the study group were three times more likely than respondents in the control group to report using a medication cost-lowering strategy. Respondents who were younger and had limited prescription drug coverage, lower household income, higher educational status, and poorer health status were at increased risk of adopting a cost-lowering strategy.

Mesh:

Year:  2008        PMID: 18499881     DOI: 10.2146/ajhp070478

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  7 in total

1.  Coping strategies used by patients infected with hepatitis C virus who are facing medication costs.

Authors:  Chiranjeev Sanyal; Ethel Langille Ingram; Ingrid S Sketris; Kevork M Peltekian; Susan Kirkland
Journal:  Can J Hosp Pharm       Date:  2011-03

Review 2.  Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review.

Authors:  Jennifer M Polinski; Elaine Kilabuk; Sebastian Schneeweiss; Troyen Brennan; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2010-09       Impact factor: 5.562

Review 3.  Medicare beneficiaries' knowledge of and choices regarding Part D, 2005 to the present.

Authors:  Jennifer M Polinski; Aman Bhandari; Uzaib Y Saya; Sebastian Schneeweiss; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2010-04-06       Impact factor: 5.562

Review 4.  Medicare Part D and quality of prescription medication use in older adults.

Authors:  Denys T Lau; Becky A Briesacher; Daniel R Touchette; JoAnn Stubbings; Judy H Ng
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

5.  Out-of-plan pharmacy use by members of a managed care organization.

Authors:  Thomas Delate; Gale Albrecht; Kari L Olson
Journal:  Perm J       Date:  2012

6.  Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.

Authors:  Jennifer M Polinski; William H Shrank; Haiden A Huskamp; Robert J Glynn; Joshua N Liberman; Sebastian Schneeweiss
Journal:  PLoS Med       Date:  2011-08-16       Impact factor: 11.069

7.  Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.

Authors:  Leslie Hazel-Fernandez; Anthony M Louder; Shonda A Foster; Claudia L Uribe; Russel T Burge
Journal:  BMC Musculoskelet Disord       Date:  2013-01-03       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.